Abbott plans marketing push for glucose monitors beyond diabetes  — Morphic kept it simple in M&A maneuvers, staying focused on Lilly to reel in $3.2B buyout— FDA launches innovation hub to spur rare disease R&D —http://bit.ly/w28kSd #cgms #glucosemonitoring #abbottlabs #elililly #innovation #fda #rarediseases #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

ASCO: With Opdivo-Yervoy combo, Bristol Myers calls Roche and AstraZeneca's bets in first-line liver cancer—FDA panel to review psychedelic drug MDMA for first time — Abbott’s OTC glucose monitor ‘will grow the market’—http://bit.ly/w28kSd #asco2024 #oncology #cancer #bristolmyerssquibb #livercancer #mdma #fda #abbottlabs #cgm #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma